Erik de Clercq

Director/Board Member at FermaVir Pharmaceuticals LLC

Health Technology

Profile

Erik De Clercq has been a Director of FermaVir Pharmaceuticals, Inc. since August 16, 2005 and FermaVir Research, Inc. since March, 2005.
He has been working with Rega Institute in Leuven since 1977.
Dr. De Clercq is a Professor of the Medical School at Leuven University, Leuven, Belgium.
He is Chairman and a Director of the Rega Institute and the Rega Foundation and Chairman of the Department of Microbiology and Immunology at Leuven University.

Erik de Clercq active positions

Companies	Position	Start
FermaVir Pharmaceuticals LLC FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY.	Director/Board Member	15/08/2005

All active positions of Erik de Clercq

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Erik de Clercq's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
FermaVir Pharmaceuticals LLC FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY.	Health Technology